STOK Stoke Therapeutics Inc

Price (delayed)

$29.3

Market cap

$1.82B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.84

Enterprise value

$1.67B

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 22

Stoke Therapeutics, is a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines. Using the company's proprietary TANGO (Targeted Augmentation of ...

Highlights
Stoke Therapeutics's quick ratio has soared by 70% from the previous quarter and by 7% YoY
Stoke Therapeutics's equity has increased by 13% YoY and by 12% from the previous quarter
The revenue has plunged by 83% YoY and by 83% from the previous quarter
The company's gross profit has shrunk by 83% YoY and by 83% QoQ

Key stats

What are the main financial stats of STOK

STOK stock price

How has the Stoke Therapeutics stock price performed over time
Intraday
-1.18%
1 week
0.86%
1 month
-3.59%
1 year
116.88%
YTD
-7.69%
QTD
-10.45%

Financial performance

How have Stoke Therapeutics's revenue and profit performed over time
Revenue
$32.08M
Gross profit
$32.08M
Operating income
-$185.25M
Net income
-$169.77M
Gross margin
100%
Net margin
-529.2%
The revenue has plunged by 83% YoY and by 83% from the previous quarter
The company's gross profit has shrunk by 83% YoY and by 83% QoQ

Price vs fundamentals

How does STOK's price correlate with its fundamentals

Growth

What is Stoke Therapeutics's growth rate over time

Valuation

What is Stoke Therapeutics stock price valuation
P/E
N/A
P/B
4.39
P/S
57.6
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
52.03
The P/B is 51% above the 5-year quarterly average of 2.9 and 10% above the last 4 quarters average of 4.0
Stoke Therapeutics's equity has increased by 13% YoY and by 12% from the previous quarter
The price to sales (P/S) is 173% higher than the last 4 quarters average of 21.1 and 19% higher than the 5-year quarterly average of 48.6
The revenue has plunged by 83% YoY and by 83% from the previous quarter

Efficiency

How efficient is Stoke Therapeutics business performance

Dividends

What is STOK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for STOK.

Financial health

How did Stoke Therapeutics financials performed over time
STOK's current ratio has surged by 70% since the previous quarter and by 7% year-on-year
Stoke Therapeutics's quick ratio has soared by 70% from the previous quarter and by 7% YoY
STOK's debt is 100% smaller than its equity
Stoke Therapeutics's equity has increased by 13% YoY and by 12% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.